IngredientsKavalactones are derived from Piper methysticum, an ethnomedicinal shrub native to the Polynesian islands. The botanical name translates from Greek as "intoxicating pepper," and the plant is a member of the Piperaceae (pepper) family. Kava plants are generally found across Polynesia, Melanesia, and Micronesia. The prized part of the kava plant is the root system, because it contains the highest concentrations of the active kavalactones.
The bioactive principles of kava rhizome are mostly, if not entirely, contained in the lipid-soluble resin. The compounds of greatest pharmacological interest are the substituted α-pyrones, or kavapyrones, commonly known as kavalactones. These are neutral, nitrogen-poor compounds specifically referred to as substituted alpha-pyrones. The lactone ring is substituted by a methoxy group at the C-4 position, and the compounds vary in their substitution by either a styryl residue (e.g., yangonin, desmethoxyyangonin, kawain, and methysticin) or by a phenylethyl residue (e.g., dihydrokawain and dihydromethysticin) at the C-6 position.
Kava is an ethnomedicinal shrub with well-established anxiolytic and analgesic properties. Its main psychoactive principles, kavalactones, form a unique class of polyketides that interact with the human central nervous system through mechanisms distinct from those of conventional psychiatric drugs.
At least 15 lactones have been isolated from kava rhizome. Twenty known kavalactones have been identified. The six major kavalactones, which constitute over 96% of kavalactone content in the plant rhizome, are: dihydrokavain/dihydrokawain, kavain/kawain, dihydromethysticin, methysticin, yangonin, and desmethoxyyangonin, in order of typical proportion.
In the past, "kavain" has been used to indicate a racemic mixture resulting from chemical synthesis, and "kawain" for the naturally occurring compound, which is a dextro-isomer. Currently, the two terms are frequently used interchangeably in the scientific literature, but the term kavain has started to supersede kawain.
Analysis of the composition of kava rhizome indicates that the fresh material is on average 80% water. When dried, the rhizome consists of approximately 43% starch, 20% fibres, 12% water, 3.2% sugars, 3.6% proteins, 3.2% minerals, and 15% kavalactones, although the kavalactone component can vary between 3% and 20% of the dry weight of the rhizome, depending on the age of the plant and the cultivar.
Other main constituents of the kava rhizome include alkaloids and amides such as 1-cinnamoylpyrrolidine, 1-(m-methoxycinnamoyl)-pyrrolidine, and cepharadione A; chalcones, flavonoids, steroids (sitosterol, stigmasterol, and stigmastanol); esters (e.g., bornyl cinnamate); aliphatic alcohols; and long-chain fatty acids.
Kava also produces flavokavains, which are chalconoids with anticancer properties structurally related to kavalactones.
After a kava plant is harvested, the root is conventionally processed to generate a consumable product. In conventional and historical methods, the root is dried and ground to a powder. Modern commercial preparations include aqueous extracts, standardized dry ethanolic or acetonic extracts in capsule and tablet form, tinctures, and instant powdered concentrates. Kava products are sold in the United States as dietary supplements and in some other countries as drugs or herbal medicines. These products are promoted for anxiety and other health conditions.
Indigenous to the islands of the South Pacific, kava has been cultivated and consumed for at least 3,000 years across Fiji, Vanuatu, Tonga, Samoa, and Hawaii. The exact island where kava was first domesticated remains a topic of debate; it is widely believed to be in Vanuatu, but some believe it to be Papua New Guinea. Historically, island communities were interconnected through substantial trade networks, and kava was taken by seafarers on journeys between islands. This eventually led to the spread of kava throughout other parts of the Melanesian Islands such as Papua New Guinea and the Solomon Islands, the Polynesian Islands including Tonga, Samoa, and the Hawaiian Islands, and the Micronesian Islands.
The plant was not only consumed for its psychoactive properties but also held cultural and social significance. It marked agreements between chiefs, welcomed guests, honored the dead, sought guidance from ancestors, and opened sacred ceremonies. The installation of a new village chief, agreements between communities, or the welcoming of an important visitor always include a kava ceremony. In Tonga, the installment of the king or a noble title is not complete until a kava ceremony is conducted.
For many Pacific Islanders, the drink holds an immense amount of spiritual significance. The mental clarity and open-mindedness that come with the calming properties of kava are believed to help individuals connect and communicate with higher powers of the spiritual realm. Kava is used as an offering to ancestral spirits, gods, and chiefs as a symbol of compliance and respect to gain guidance, protection, and blessings.
Traditionally, kava was prepared by cutting the root into small pieces, being chewed by several people and spat into a bowl, where it was mixed with coconut milk. Over time, this method evolved: traditional preparation involved pounding or chewing the dried root, mixing it with water, and straining the liquid through fibrous material into a communal bowl. Historically, the beverage was made from fresh kava; preparation from dry kava emerged in response to the efforts of Christian missionaries in the 18th and 19th centuries to prohibit the drinking of kava.
In traditional medicine, kava has been used in several diseases, including asthma, different types of infections, headache, and menstrual disorders, though these uses are not supported by scientific evidence. Various preparations of kava were marketed since the 1980s, especially in Europe and North America, to manage mild anxiety, tension, and restlessness.
Kavalactones, the major pharmacologically active constituents of kava, are responsible for approximately 95% of its total activity. The six principal compounds—kavain (kawain), dihydrokavain (dihydrokawain), methysticin, dihydromethysticin, yangonin, and desmethoxyyangonin—each possess distinct pharmacological profiles and relative potencies. Several preclinical studies on the therapeutic effects of kava indicate that most of the neurobiological effects are imparted by the kavalactones, which include kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin, and desmethoxyyangonin. These kavalactones are present primarily in the root and rhizomes of the plant and consist of around 4–8% of the dried weight of those tissues.
Studies of kava extracts or kavalactones have been focused on elucidating the mechanism underlying their anti-anxiety and sleep-inducing ability, which has been attributed to modulation of the γ-aminobutyric acid (GABA) receptor. The proposed mechanism of the GABAergic effect occurs through the positive modulation of multiple benzodiazepine binding sites, including GABA-A and GABA-B, from kavain, yangonin, dehydromethysticin, and desmethoxyyangonin, through both enhanced ligand displacement and binding.
Research has clarified how this interaction differs from classical benzodiazepine pharmacology. GABA-A receptors are assumed to be the in vivo molecular target of kavalactones based on data from binding assays, but direct interaction evidence has been limited. One study characterised the functional properties of the major anxiolytic kavalactone, kavain, at human recombinant GABA-A receptor subunit combinations expressed in Xenopus oocytes using the two-electrode voltage-clamp technique, and found that kavain positively modulated all receptors tested. The psychotropic effects and topographic pattern differed from those of benzodiazepines, and data are consistent with pre-clinical models of kavain as a positive allosteric modulator of the GABA-A receptor outside the typical benzodiazepine binding site.
Numerous in vivo and in vitro studies suggest possible mechanisms including: blockade of voltage-gated sodium ion channels; reduced excitatory neurotransmitter release due to blockade of calcium ion channels; affinity for CB₁ receptors within the endocannabinoid system; enhanced ligand binding to GABA-A receptors; reversible inhibition of monoamine oxidase B; reduced neuronal reuptake of noradrenaline and dopamine; and suppression of the synthesis of the eicosanoid thromboxane A2, which antagonizes GABA-A receptor function.
Kavalactones such as kavain, dihydrokavain, methysticin, and dihydromethysticin interact with GABAergic, dopaminergic, serotonergic, and glutamatergic pathways to improve CNS modulation without producing extreme sleepiness or cognitive impairment. Pre-clinical studies also suggest mechanisms occurring within the GABA metabolic shunt, such as modulation of the calcium ion channel blockade of the monoamine oxidase-B receptor substrate, thereby inhibiting glutamate and promoting GABA synthesis.
Studies have been focused on elucidating the mechanism underlying the anti-anxiety and sleep-inducing ability of kavalactones. Recent studies on the mechanisms of action for isolated kavalactones have revealed other neuroprotective activities not directly related to their GABAergic effects. Kava has been reported to have neuroprotective effects mediated via its blocking action on voltage-gated Na⁺ and Ca²⁺ channels.
Kava has an analgesic action that is not mediated through opioid receptors, because it is not reversed by naloxone. It most likely acts by interacting with GABAergic and monoamine transmitters. The anticonvulsive properties are similar to those of local anesthetics, such as procaine, and analgesic effects appear to occur via non-opiate pathways. Kavain, dihydrokavain, methysticin, and dihydromethysticin have been found to possess significant analgesic effects in animal studies.
Several compounds of kava, such as kavain, dihydrokavain, methysticin, desmethoxyyangonin, and yangonin, are able to cross the blood–brain barrier in in vivo studies. Kavalactones pass through the blood-brain barrier and can cause behavioral changes at low concentrations.
Overview of Human Evidence
Kava products are sold and promoted for anxiety and other health conditions. There has been a fair amount of research in people on the use of kava for anxiety, but few studies have been done on other conditions.
Compared with placebo, kava extract might be an effective symptomatic treatment for anxiety, although at present the effect size seems to be small. The effect lacks robustness as indicated by sensitivity analyses and is based on a relatively small sample. Nonetheless, reviewed trials which could not be included in the meta-analysis support the findings and suggest that kava is beneficial for patients with anxiety when compared with placebo. Larger rigorous trials, particularly long-term studies, are needed.
In a systematic review assessing the safety of kava, two drug monitoring studies including a total of 7,078 patients taking kava extract equivalent to 105 mg to 240 mg kavalactones per day for 5 to 7 weeks were located. In these studies no cases of hepatotoxicity emerged. Two post-marketing surveillance studies, including 1,673 patients who received kava extract equivalent to 120 mg kavalactones daily for 5 weeks and 2,944 other patients who received 400 mg kavain daily for 4 weeks, corroborate this and report no hepatotoxic events.
Neuroimaging Evidence
A study investigated dorsal anterior cingulate (dACC) GABA levels in 37 adult participants with generalized anxiety disorder. GABA was measured using proton magnetic resonance spectroscopy at baseline and following an eight-week administration of kava (standardised to 120 mg kavalactones twice daily) in 20 participants, or placebo in 17.
EEG Studies
A double-blinded, placebo-controlled EEG brain-mapping study conducted in healthy human volunteers demonstrated that single doses of the kavalactone kawain at 200, 400, and 600 mg respectively caused a dose-dependent shift towards lower brain wave frequencies (delta, theta, and alpha waves), and indicated a more sedating effect in the higher dosing range.
Evidence Limitations
Clinical data suggest moderate benefits with kava as short-term use for generalized anxiety disorder, and no differences in withdrawal or addiction versus placebo. Several studies support the use of kava for relieving anxiety, but a recent double-blind placebo-controlled trial did not find benefit. Although kava has been suggested as an alternative to benzodiazepines, an internet-based study and a randomized clinical trial suggest that kava is not superior to placebo in reducing anxiety.
Kava supplements may be helpful for anxiety, but they may need to be taken for several weeks to produce an effect. Kava does not appear to be helpful for symptoms of generalized anxiety disorder specifically. There is not enough evidence to show whether kava is helpful for any other conditions. The overall evidence base for anxiety is therefore moderate but mixed: multiple positive RCTs exist, yet the effect size is modest, trials are generally of short duration and small sample size, and some high-quality trials have been negative.
The medicinal uses of kava supported by clinical data include the short-term treatment of mild types of anxiety and insomnia. A 2004 study shined light on kava's ability to promote sleep for those wrestling with stress-induced insomnia, concluding that sleep disturbances associated with anxiety can be effectively and safely treated with kava, without the dependency brought on by many sleep aids. This randomized controlled trial found statistically significant differences in favor of kava for quality of sleep.
The research is less robust than the anxiety data, but several trials have documented improved sleep quality alongside anxiety reduction in people using kava. The effect appears most consistent when poor sleep is being driven by anxiety rather than by primary insomnia or circadian disruption. The evidence for sleep as a standalone indication, separate from anxiety, is therefore preliminary and limited.
Recent studies on the mechanisms of action for isolated kavalactones have revealed neuroprotective activities not directly related to their GABAergic effects. Kavalactones have demonstrated neuroprotective effects, supporting the recovery of neurological deficits after cerebral infarction in animal models, effects which have been attributed to calcium channel agonism, sodium channel blocking, inhibition of monoamine oxidase, and inhibition of noradrenaline uptake. These findings are currently preclinical only; no human trials have established neuroprotection as a clinical endpoint.
Flavokavains, including flavokavain B, have demonstrated anticancer efficacy by inducing ROS-mediated apoptosis in tumor cells; nevertheless, they may potentially be hepatotoxic. Kava also produces flavokavains, which are chalconoids with anticancer properties structurally related to kavalactones. The anticancer evidence is currently preclinical (in vitro and animal models); rigorous human clinical trials are lacking.
Kavalactones in kava are thought to be the active constituent that produces skeletal muscle relaxation, non-narcotic anesthesia, and local anesthetic effects. Some reports indicate that kava preparations may have analgesic, spasmolytic, neuroprotective, and antimitotic activities. Clinical uses historically attributed to kava in the literature include local anesthetic, neuroprotective, anti-inflammatory, memory enhancement, anticonvulsant, and analgesic activities. The analgesic and local anaesthetic evidence base is largely preclinical and observational, without the benefit of rigorous human clinical trials.
Clinical studies have confirmed that kava and kavalactones are effective in the treatment of anxiety at subclinical and clinical levels, including anxiety associated with menopause, and various other medical conditions. However, the evidence base specific to menopause remains limited and primarily derived from small trials.
Kavalactones have been studied in relation to the following body systems and health domains:
Kavalactones are available in the following dosage forms:
The following dosages appear in the cited clinical literature:
In the 1990s and early 2000s, multiple case reports emerged linking kava extracts containing kavalactones to acute liver failure, including instances requiring liver transplantation and fatalities. These reports, primarily from Europe and the United States, prompted regulatory actions such as the European Union's ban on kava products in 2002 due to concerns over severe hepatotoxicity. The estimated incidence of such events was extremely low, approximately 1 in 1 million users or daily doses, based on sales data and reported cases during that period.
Concerns have arisen regarding the safety of kava products, in particular due to reports of liver injury. For this reason, the use of kava has been banned or restricted in many countries of the world such as Germany, Switzerland, France, Canada, and Great Britain.
The World Health Organization found that kava-related hepatotoxicity was likely due to quality problems, adulteration of the root with other parts of the plant, use of ethanol- rather than water-based extraction, and in some cases interactions between kava and other drugs/herb preparations or chronic alcohol use. As a result of these assessments, the ban on kava use was lifted in 2014, and kava is again available for use in Europe.
Dozens of clinical data revealed the hepatotoxicity effect which is indirectly or directly associated with kava consumption, and most of the evidence currently seems to point to the flavokavains in kava as responsible.
Proposed mechanisms for kava-induced hepatotoxicity include inhibition of cytochrome P450 enzymes, which may lead to idiosyncratic reactions by altering drug metabolism and promoting toxic metabolite formation.
Various kava products have been linked to rare cases of liver injury, some of which have been serious or even fatal. The risk is higher with alcoholic or acetonic extracts, or concentrated forms like pills. Water-based kava extracts in moderate doses are considered safer, but should not be consumed with alcohol, particularly by those with a history of liver issues.
Reported adverse effects include headaches, hepatotoxicity, urticaria, and reversible dermopathy. Kava dermopathy (also called "kanikani" or "kava ichthyosis") is a dry, scaly skin condition associated with chronic heavy use and is considered reversible upon cessation.
In vitro studies investigated the inhibition of P450 enzymes by kava extract and individual kavalactones in human liver microsomes (HLMs). Whole kava extract caused concentration-dependent decreases in P450 activities, with significant inhibition of the activities of CYP1A2 (56% inhibition), CYP2C9 (92%), CYP2C19 (86%), CYP2D6 (73%), CYP3A4 (78%), and CYP4A9/11 (65%).
Individual kavalactone inhibition profiles differ: kavain did not inhibit these enzymes, but there was significant inhibition of CYP2C9 by desmethoxyyangonin, methysticin, and dihydromethysticin; of CYP2C19 by dihydromethysticin; of CYP2D6 by methysticin; and of CYP3A4 by desmethoxyyangonin, methysticin, and dihydromethysticin.
These data indicate that kava has a high potential for causing drug interactions through inhibition of P450 enzymes responsible for the majority of the metabolism of pharmaceutical agents.
Kavalactones are potent inhibitors of several CYP450 enzymes, suggesting a potential for causing pharmacokinetic interactions with drugs and other herbs that are metabolized by the same CYP450 enzymes. This potential to modulate the activity of drug-metabolizing enzymes may influence pharmacokinetic interactions for a variety of medications including antiplatelet agents, diuretics, other potentially hepatotoxic drugs, and anticancer drugs.
There are reports of significant interaction of kava with other CNS depressant drugs, and hence concurrent use with CNS depressant drugs is not advised. Controlled trials suggest that P. methysticum extracts do not impair cognitive performance or potentiate the effects of central nervous system depressants; however, a synergistic effect is possible for substances acting on the central nervous system, especially those which cause sedation or lethargy. Medications and substances that may have additive effects when taken concomitantly include alcohol and barbiturates, anxiolytic medications (e.g., SSRIs and benzodiazepines), analgesics and opioids, and dopaminergic medications.
Through targeted actions on the gamma-aminobutyric acid (GABA) pathway, kava is described as a non-addictive, non-hypnotic anxiolytic. Clinical data show no differences in withdrawal or addiction versus placebo. Clinical use shows no signs of addiction or withdrawal.
While kava appears safe in traditional South Pacific use, caution is advised, especially during pregnancy, for people with pre-existing liver conditions, or when combined with alcohol consumption, prescription drugs, or dietary supplements.
A WHO pharmacovigilance analysis revealed that the majority of hepatotoxicity case reports were incomplete or unassessable, only 8 cases were coded as "probable," most patients were using acetonic or ethanolic extract products rather than traditional water kava, and many cases involved pre-existing liver conditions, heavy alcohol use, or concurrent use of other hepatotoxic medications. Patients taking organic solvent extracts showed a higher rate of liver events than patients taking synthetic single-kavalactone products.
Health conditions that Kavalactones may help support.
Kavalactones are the primary bioactive compounds of kava (Piper methysticum) responsible for its anxiolytic effects. They directly potentiate GABA-A receptors and inhibit norepinephrine reuptake. Multiple clinical trials studying standardized kava extracts (delivering defined kavalactone content) demonstrate anxiolytic effects. The evidence base for kavalactones mirrors the kava evidence base.
Kavalactones are the active constituents of kava root (Piper methysticum) standardized in all kava clinical trials. They modulate GABA-A receptors (novel binding site), block voltage-gated sodium and calcium channels, and inhibit MAO-B. Multiple RCTs including two head-to-head vs. oxazepam and buspirone and a Cochrane review confirm efficacy for anxiety at 70–240 mg/day. Hepatotoxicity risk is linked to non-traditional extraction methods.
Kavalactones are the primary psychoactive compounds in kava (Piper methysticum) and are responsible for its anxiolytic and sedative effects. Multiple RCTs and a meta-analysis support their efficacy for anxiety-related insomnia. They modulate GABA-A receptors and sodium/calcium channels.
Kavalactones are the primary bioactive compounds of kava responsible for its anxiolytic and nervous system-calming properties. They modulate GABA-A receptors, inhibit voltage-gated ion channels, and multiple RCTs confirm their efficacy for anxiety reduction.
Kavalactones are the primary bioactive constituents of kava root responsible for its clinically demonstrated anxiolytic effects. They modulate GABA-A receptors, block voltage-gated ion channels, and reduce limbic excitability. Multiple RCTs of standardized kavalactone-containing extracts show significant reductions in anxiety scores versus placebo.
The primary bioactive compounds in Kava (Piper methysticum), responsible for its anxiolytic and stress-reducing effects. Clinical reviews confirm kavalactones modulate GABA-A receptors and demonstrate mild-to-moderate efficacy for stress and anxiety reduction in multiple RCTs and meta-analyses.
Body systems that Kavalactones may help support.
Go back